Emulation of the SOUL Diabetes Trial in Healthcare Claims

CompletedOBSERVATIONAL

Enrollment

43,650

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Oral semaglutide

New use of oral semaglutide dispensing claim is used as the exposure.

DRUG

Sitagliptin

New initiation of sitagliptin dispensing claim is used as the reference.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT06659718 - Emulation of the SOUL Diabetes Trial in Healthcare Claims | Biotech Hunter | Biotech Hunter